1. Early versus Conventional Treatment for Patent Ductus Arteriosus in Preterm Infants
- Author
-
Ermengol Coma Redon, Queralt Ferrer Menduiña, Ángeles Linde Sillo, Dimpna C. Albert, Félix Castillo Salinas, and Júlia Candel-Pau
- Subjects
Male ,Pediatrics ,medicine.medical_specialty ,Time Factors ,Birth weight ,Indomethacin ,Population ,Gestational Age ,Risk Assessment ,Drug Administration Schedule ,Cohort Studies ,Treatment and control groups ,Ductus arteriosus ,medicine ,Humans ,education ,Ductus Arteriosus, Patent ,Retrospective Studies ,education.field_of_study ,Chi-Square Distribution ,Dose-Response Relationship, Drug ,Descriptive statistics ,business.industry ,Infant, Newborn ,Conventional treatment ,Obstetrics and Gynecology ,Gestational age ,Cardiovascular Agents ,Retrospective cohort study ,Echocardiography, Doppler ,Survival Rate ,Treatment Outcome ,medicine.anatomical_structure ,Pediatrics, Perinatology and Child Health ,Female ,business ,Infant, Premature ,Follow-Up Studies - Abstract
Objective After the introduction of a new protocol based on the early treatment with indomethacin for patent ductus arteriosus, the objective of this study was to assess the safety and efficacy of this new practice in comparison with the safety and efficacy of the conventional treatment in a high-risk population. Study Design We conducted a retrospective cohort study including 154 newborns with an average gestational age of 26.4 weeks (1.37 standard deviation) and an average birth weight of 855 g (201.5 standard deviation). A statistically descriptive analysis was performed with SPSS Statistics Pack version 17.0. Results and Conclusions We did not find any statistically significant differences in the clinical features of the two treatment groups, nor in the main efficacy, morbidity, and mortality results.
- Published
- 2012